SER (Serina Therapeutics) Change In Payables And Accrued Expense : $-1.86 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Change In Payables And Accrued Expense?

Serina Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $0.05 Mil. It means Serina Therapeutics's Accounts Payable & Accrued Expense increased by $0.05 Mil from Dec. 2024 to Mar. 2025 .

Serina Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $-1.26 Mil. It means Serina Therapeutics's Accounts Payable & Accrued Expense declined by $1.26 Mil from Dec. 2023 to Dec. 2024 .

Serina Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Serina Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Change In Payables And Accrued Expense Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

-0.38

0.25

-1.26

Serina Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial						0.65	-1.95	0.72	-0.68	0.05

Serina Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.86 Mil.

Serina Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

2BO:Germany

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.